跳转至内容
Merck
CN
  • Long-term results of cornea collagen cross-linking with riboflavin for keratoconus.

Long-term results of cornea collagen cross-linking with riboflavin for keratoconus.

Indian journal of ophthalmology (2013-08-09)
Vinay Agrawal
摘要

Corneal collagen cross-linking with riboflavin and UVA light (CXL) is the only method designed to arrest the progression of keratoconus. Visual improvement generally starts 3 months after treatment. Reduction is coma seen on aberrometry in early postoperative phase is also responsible for the improvement in visual acuity. In the light of currently available data we can thus say that CXL is a safe procedure that is successful in arresting keratoconus.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
(−)-核黄素, from Eremothecium ashbyii, ≥98%
Supelco
核黄素 (B2), analytical standard
Sigma-Aldrich
(−)-核黄素, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥98%
Supelco
核黄素, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
(−)-核黄素, meets USP testing specifications
USP
核黄素, United States Pharmacopeia (USP) Reference Standard
核黄素, European Pharmacopoeia (EP) Reference Standard
(−)-核黄素, European Pharmacopoeia (EP) Reference Standard